Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities
A multi-ingredient patch containing acetyl octapeptide-3 improved measured wrinkle roughness relative to the comparator.
Study design
28-day split-face combination-patch comparison
Model / population
Adults with eye wrinkles
Sample size
Enrolled: 24; Completed: 21
Route studied
Cutaneous dissolving microneedle patch
Limitations. Does not isolate SNAP-8. Small short study; no inference to ordinary cream, systemic injection or research vials. Several authors had manufacturer affiliations.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Respondents reported improvement following BPC157 alone or BPC157 plus thymosin beta-4.
Study design
Uncontrolled retrospective review with telephone outcomes
Model / population
Patients with heterogeneous knee pain
Sample size
Respondents: 16; BPC only: 12; Combination: 4
Route studied
Intra-articular knee injection
Limitations. Selection and recall bias, tiny combination group and no control. Cannot establish tissue healing, causality, safety or equivalence of TB4 to marketed TB500.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
Identified acetylated LKKTETQ in the analyzed product.
Study design
Analytical identification and detection-method study
Model / population
Analyzed product and synthesized reference
Limitations. An identity study, not clinical efficacy. A commercial name cannot establish sequence, terminal modifications or equivalence to full-length thymosin beta-4.
Defines an approved prescription-product context for excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.
Study design
FDA approved-product labeling inspected at source check
Limitations. Specific finished-product labeling is not approval of supplier research vials. Label versions and indications require ongoing checks.
Documents approved prescription-product context, contraindications and warnings for the named finished product.
Study design
FDA approved-product labeling inspected at source check
Limitations. Approval is product-specific, not blanket approval of research materials. This source check does not replace current labeling or medical advice.
Formulation Composition and Process Affect Counterion for CSP7 Peptide
Counterion loss and formulation-dependent pH shifts affected CSP7 aggregation and stability.
Study design
NMR, chromatography and physical-stability testing across lyophilization and formulation conditions
Model / population
in-vitro peptide formulations
Route studied
not applicable; laboratory formulation study
Limitations. Compound-specific bench evidence; no human cohort. Does not validate retail acetic-acid water, another peptide, injection safety or a universal storage period.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Reported increased energy expenditure and fatty-acid oxidation and reduced fat accumulation in studied models.
Study design
preclinical metabolic experiments
Model / population
mouse metabolic models including diet-induced obesity
Route studied
intraperitoneal administration in mouse experiments
Limitations. Results depend on model and endpoint; not every metabolic endpoint improved. No human weight-loss or safety conclusion; sample sizes vary by experiment.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Reported sustained increases in GH and IGF-I after CJC-1295 administration.
Study design
Two randomized double-blind placebo-controlled ascending-dose studies; 28 and 49 days
Model / population
Healthy adults aged 21–61
Route studied
Subcutaneous long-acting analogue
Limitations. Hormonal and pharmacokinetic endpoints, not long-term clinical benefit or a blend trial. Albumin-binding study drug must not be equated with an unspecified no-DAC / modified-GRF product; total n not established from the inspected abstract.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Pulsatility persisted while trough and mean GH and IGF-I increased.
Study design
Overnight endocrine sampling before and one week after administration
Model / population
Healthy men aged 20–40
Route studied
Injected albumin-binding CJC-1295
Limitations. Small physiology study; abstract does not establish a total n. Preserved pulsatility is not proof of clinical efficacy, long-term safety, a no-DAC exposure profile or benefit from adding ipamorelin.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Modeled ipamorelin disposition and a transient GH response.
Study design
Dose-escalation PK/PD experiment; eight subjects at each dose level
Model / population
Healthy male volunteers
Route studied
Intravenous infusion
Limitations. The abstract reports subjects per dose level, not a verified distinct-participant total. Not a trial of a subcutaneous research vial, combination, anti-aging or body-composition intervention.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
No statistically significant difference in the key solid-meal-tolerance endpoint.
Enrolled: 117; Safety and modified intent to treat: 114
Route studied
Intravenous infusion
Limitations. Small proof-of-concept study with heterogeneous underlying conditions. A postoperative endpoint is not healthy-person fat-loss or recovery evidence, nor a trial of an ipamorelin blend.
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group
Mean height velocity increased over follow-up in the studied children.
Study design
Multicenter open-label one-year study
Model / population
Previously untreated prepubertal children with GH deficiency
Sample size
Treated: 110; Eligible for efficacy analysis: 86
Route studied
Subcutaneous GHRH-(1-29)
Limitations. Open-label design and a subset eligible for efficacy analysis; not a controlled demonstration of adult anti-aging, fat-loss or functional benefit.
FDA determination concerning withdrawal of Geref (sermorelin acetate) injection products
FDA determined the specified discontinued products were not withdrawn for safety or effectiveness reasons.
Study design
Federal Register regulatory determination
Model / population
Named historical Geref products
Limitations. Historical product-specific determination, not proof of present marketing or approval of every compounded formulation, research vial or adult-use claim.
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
Reported acute LH and infusion-related reproductive-hormone responses.
Study design
Small bolus dose-response and infusion physiology experiments
Model / population
Healthy men; individual experiments reported n of six or four
Route studied
Intravenous bolus and infusion
Limitations. Small experimental groups; unique total n not inferred by summing groups. Not a fertility, live-birth, persistent testosterone-benefit or personal-use safety trial; do not substitute kisspeptin-54 evidence.
The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans
Gonadotropin responses differed by sex and menstrual phase in the tested conditions.
Study design
Small endocrine experiments comparing sex and menstrual-phase responses
Model / population
Healthy men and women; four or five participants per experimental group
Route studied
Intravenous bolus; additional subcutaneous and infusion experiments in women
Limitations. Not a clinical fertility-outcome trial. Group sizes are small and a unique combined n is not established here; no universal hormone-response or treatment conclusion.
Adults with obesity or overweight plus weight-related condition
Sample size
338
Route studied
Subcutaneous trial formulation
Limitations. Primary endpoint was week 24. Limited size/duration; gastrointestinal events and heart-rate changes. Not evidence for unrelated research products.
Limitations. Open-label, specific treatment regimens/population. Weight endpoint does not establish superiority for cardiovascular outcomes or every individual.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Primary composite cardiovascular event occurred in 6.5% versus 8.0% with placebo; hazard ratio 0.80.
Study design
Randomized placebo-controlled cardiovascular outcomes trial; mean follow-up 39.8 months
Model / population
People with established cardiovascular disease and overweight/obesity, without diabetes
Sample size
17604
Route studied
Subcutaneous semaglutide trial intervention
Limitations. Established cardiovascular disease population, not universal primary prevention. Relative reduction is not a 20-percentage-point absolute reduction. Adverse-event discontinuation was higher.
Once-weekly cagrilintide for weight management in people with overweight and obesity
Cagrilintide groups had mean weight reductions of 6.0–10.8% versus 3.0% with placebo under the trial-product estimand.
Study design
Randomized placebo- and active-controlled dose-finding phase 2; 26 weeks
Model / population
Adults without diabetes, with obesity or qualifying overweight
Sample size
706
Route studied
Subcutaneous trial intervention
Limitations. Specific population, limited duration and estimand; active treatments not mutually masked. Gastrointestinal and administration-site events. Not combination-product evidence.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Combination treatment-policy mean weight change was −20.4% versus −3.0% with placebo.
Study design
Randomized placebo- and active-controlled; 68 weeks; lifestyle intervention in all groups
Model / population
Adults with overweight/obesity without diabetes
Sample size
3417
Route studied
Subcutaneous specified combination and component trial arms
Limitations. Combination result is not cagrilintide-alone efficacy; gastrointestinal events common. Does not validate independently manufactured blends or establish every long-term outcome.
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Reported body-weight/fat and beta-3-receptor-expression changes in studied mice; knockout experiments interrogated the pathway.
Study design
Mechanistic chronic-treatment and knockout mouse experiments
Model / population
Obese, wild-type and beta-3-adrenergic-receptor knockout mice
Route studied
Intraperitoneal administration in chronic mouse experiments
Limitations. Animal model and route, not human obesity efficacy. Exact experiment-specific sample sizes not stated in inspected abstract.
FDA Pharmacy Compounding Advisory Committee briefing: AOD-9604
OPTIONS study had 536 enrolled and 502 randomized; FDA reports no significant primary weight-loss advantage with oral AOD-9604 over placebo.
Study design
Regulatory evidence assessment of clinical reports and sponsor disclosures; not a newly conducted trial
Model / population
Human obesity development program and nominated routes
Route studied
Reviewed oral and intravenous information; other routes lacked relevant clinical support
Limitations. Underlying reports had methodological/detail limits. Document review must not be presented as a new trial, marketing approval or a comprehensive proof about every hypothetical formulation.
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Reported BDNF increase in basal forebrain, not cerebellum, under tested conditions.
Study design
Binding and regional neurotrophin experiments
Model / population
Rat brain
Route studied
Intranasal
Limitations. Regional molecular endpoint in rats, not human cognitive efficacy or long-term safety.
Peptides of pineal gland and thymus prolong human life
Reported health/mortality findings with Thymalin, Epithalamin or combinations—not isolated Epithalon.
Study design
Long-term clinical report involving different peptide preparations
Model / population
Elderly and older people
Sample size
266
Limitations. Identity mismatch prohibits presenting this as proof of the defined tetrapeptide's human lifespan effect; methods require separate critical appraisal.
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Tracked plasma and urinary metabolites during and after infusion.
Study design
Small infusion metabolite pilot
Model / population
Human volunteers
Sample size
Test: 8; Control: 3
Route studied
Intravenous NAD+
Limitations. Metabolic handling, not rejuvenation or disease-treatment efficacy; disappearance from plasma does not prove a particular intracellular destination.
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
Reported infusion symptoms and differing tolerability; not randomized efficacy evidence.
Study design
Retrospective commercial-setting comparison
Model / population
Clients receiving NAD+ or NR infusions
Route studied
Intravenous
Limitations. Short follow-up, selected setting, commercial author affiliations; exploratory biomarkers do not establish health benefit. Abstract and figure text differ on ALP direction, so that result is not summarized here.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Improved desire and desire-related distress scores compared with placebo; nausea, flushing and headache were more common with bremelanotide.
Study design
Two 24-week randomized double-blind placebo-controlled trials
Model / population
Premenopausal women with HSDD
Sample size
Randomized: 1267; Safety: 1247; Efficacy: 1202
Route studied
Subcutaneous study formulation
Limitations. Specific population, formulation and endpoints; not evidence for general sexual enhancement, men or research-vendor preparations. Industry-funded studies.
Limitations. Affiliated supplier document, not a formula-specific clinical trial or independent content assay. Component research does not establish mixture benefit or synergy.
Try a compound name, remove a search word or select a different type. Clear filters to see the complete index.
Follow the source, not just the summary
This index is deliberately selective. It does not include every relevant study, and missing records are not evidence that no research exists. Search PubMed for the wider literature.